| Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non–small cell lung cancer M Khorrami, P Prasanna, A Gupta, P Patil, PD Velu, R Thawani, ... Cancer immunology research 8 (1), 108-119, 2020 | 225 | 2020 |
| Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, A Achufusi, P Armand, ... Journal of the National Comprehensive Cancer Network 20 (4), 387-405, 2022 | 176 | 2022 |
| Primary pulmonary artery sarcoma: a close associate of pulmonary embolism—20-year observational analysis D Bandyopadhyay, TS Panchabhai, NS Bajaj, PD Patil, MC Bunte Journal of thoracic disease 8 (9), 2592, 2016 | 113 | 2016 |
| CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective … P Vaidya, K Bera, A Gupta, X Wang, G Corredor, P Fu, N Beig, ... The Lancet Digital Health 2 (3), e116-e128, 2020 | 107 | 2020 |
| Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. F Skoulidis, KC Arbour, MD Hellmann, PD Patil, ME Marmarelis, ... Journal of Clinical Oncology 37 (15_suppl), 102-102, 2019 | 104 | 2019 |
| Combination of peri-and intratumoral radiomic features on baseline CT scans predicts response to chemotherapy in lung adenocarcinoma M Khorrami, M Khunger, A Zagouras, P Patil, R Thawani, K Bera, P Rajiah, ... Radiology: Artificial Intelligence 1 (2), 180012, 2019 | 93 | 2019 |
| Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade P Vaidya, K Bera, PD Patil, A Gupta, P Jain, M Alilou, M Khorrami, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 75 | 2020 |
| Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients M Khunger, PD Patil, A Khunger, M Li, B Hu, S Rakshit, A Basu, N Pennell, ... PloS one 13 (10), e0197743, 2018 | 69 | 2018 |
| Managing human bites PD Patil, TS Panchabhai, SC Galwankar Journal of Emergencies, Trauma, and Shock 2 (3), 186-190, 2009 | 62 | 2009 |
| Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features M Khorrami, P Jain, K Bera, M Alilou, R Thawani, P Patil, U Ahmad, ... Lung Cancer 135, 1-9, 2019 | 60 | 2019 |
| An autopsy study of maternal mortality: a tertiary healthcare perspective TS Panchabhai, PD Patil, DR Shah, AS Joshi Journal of postgraduate medicine 55 (1), 8-11, 2009 | 46 | 2009 |
| Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC MV Negrao, HA Araujo, G Lamberti, AJ Cooper, NS Akhave, T Zhou, ... Cancer discovery 13 (7), 1556-1571, 2023 | 43 | 2023 |
| Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study M Khorrami, K Bera, P Leo, P Vaidya, P Patil, R Thawani, P Velu, P Rajiah, ... Lung Cancer 142, 90-97, 2020 | 36 | 2020 |
| RaPtomics: integrating radiomic and pathomic features for predicting recurrence in early stage lung cancer P Vaidya, X Wang, K Bera, A Khunger, H Choi, P Patil, V Velcheti, ... Medical Imaging 2018: Digital Pathology 10581, 172-182, 2018 | 31 | 2018 |
| Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab K Jazieh, M Khorrami, A Saad, M Gad, A Gupta, P Patil, VS Viswanathan, ... Journal for Immunotherapy of Cancer 10 (3), 2022 | 30 | 2022 |
| Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead PD Patil, M Burotto, V Velcheti Expert review of molecular diagnostics 18 (3), 297-305, 2018 | 25 | 2018 |
| Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI). B Thapa, J Roopkumar, AS Kim, L Gervaso, PD Patil, C Calabrese, ... Journal of Clinical Oncology 37 (15_suppl), e14151-e14151, 2019 | 24 | 2019 |
| Pulmonary artery pseudoaneurysm: a rare cause of fatal massive hemoptysis H Koneru, S Biswas Roy, M Islam, H Abdelrazek, D Bandyopadhyay, ... Case reports in pulmonology 2018, 2018 | 24 | 2018 |
| OA09. 03 Pembrolizumab in combination with platinum-based chemotherapy in recurrent EGFR/ALK-positive non-small cell lung Cancer (NSCLC) S Gadgeel, K Dziubek, M Nagasaka, T Braun, K Hassan, H Cheng, ... Journal of Thoracic Oncology 16 (10), S863, 2021 | 23 | 2021 |
| Immune check point inhibitor–associated glomerulonephritis T Ashour, G Nakhoul, P Patil, P Funchain, L Herlitz Kidney international reports 4 (2), 355-359, 2019 | 23 | 2019 |
